HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED IN SECOND LINE WITH ALECTINIB

被引：0
|
作者：
Greillier, L. [1 ]
Tuzelet, V [2 ]
Cadranel, J. [3 ]
Thiberville, L. [4 ]
Chouaid, C. [5 ]
Girard, N. [6 ]
Cortot, A. B. [7 ]
Felicio, H. [8 ]
Weber, V [8 ]
Pau, D. [8 ]
机构：
[1] APHM, Marseille, France
[2] Keyrus Biopharma, La Chapelle Sur Erdre, France
[3] Hop Tenon, Paris, France
[4] Hop Charles Nicolle, Rouen, France
[5] Creteil Univ Hosp, Dept Chest Med, Creteil, France
[6] Inst Curie, Paris, France
[7] CHRU Lille, Lille, France
[8] Roche, Boulogne, France
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN17
引用
收藏
页码：S423 / S423
页数：1
相关论文
共 50 条
  • [1] Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?
    van der Wekken, Anthonie J.
    Kok, Klaas
    Groen, Harry J. M.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2130 - S2132
  • [2] Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer
    Zhu, Viola
    Ou, S. H.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 509 - 514
  • [3] Health-related quality of life (HRQOL) in patients with ALK plus non-small cell lung cancer (NSCLC) in the phase III CROWN study
    Liu, G.
    Iadeluca, L.
    Reisman, A.
    Blackhall, F.
    Mazieres, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1056 - S1056
  • [4] Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK plus non-small cell lung cancer (NSCLC): Data from ALINA
    Nishio, Makoto
    Wu, Yi-Long
    Barlesi, Fabrice
    Ahn, Jin Seok
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Hochmair, Maximilian
    Tanaka, Hiroshi
    Glogowski, Maciej
    Rittmeyer, Achim
    Fidler, Mary J.
    Wrona, Anna
    Mamolo, Carla
    Cardona, Andres
    Ruf, Thorsten
    Smoljanovic, Vlatka
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer
    Ando, Chihiro
    Ichihara, Eiki
    Nishi, Tatsuya
    Morita, Ayako
    Hara, Naofumi
    Takada, Kenji
    Nakasuka, Takamasa
    Watanabe, Hiromi
    Kano, Hirohisa
    Nishii, Kazuya
    Makimoto, Go
    Kondo, Takumi
    Ninomiya, Kiichiro
    Fujii, Masanori
    Kubo, Toshio
    Ohashi, Kadoaki
    Matsuoka, Ken-ichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    CANCER SCIENCE, 2023, 114 (11) : 4343 - 4354
  • [6] Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    McKeage, Kate
    DRUGS, 2015, 75 (01) : 75 - 82
  • [7] Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Kate McKeage
    Drugs, 2015, 75 : 75 - 82
  • [8] Tumor Volume Nadir in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Treated With Alectinib
    Nishino, Mizuki
    Wei, Zihan
    Mazzola, Emanuele
    Hino, Takuya
    Tseng, Shu-Chi
    Sanchez, Michelle E.
    Hatabu, Hiroto
    Johnson, Bruce E.
    Awad, Mark M.
    JCO PRECISION ONCOLOGY, 2023, 7
  • [9] Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study
    Perol, M.
    Dixmier, A.
    Barlesi, F.
    Debieuvre, D.
    Raspaud, C.
    Auliac, J. B.
    Benoit, N.
    Bombaron, P.
    Moro-Sibilot, D.
    Asselain, B.
    Cotte, F-E.
    Lamoureux, P.
    Karam, N.
    Ozan, N.
    Calvet, C.
    Bryan, B.
    Allan, V.
    Valette, C. Audigier
    ANNALS OF ONCOLOGY, 2019, 30 : 46 - 46
  • [10] Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure
    Oya, Yuko
    Yoshida, Tatsuya
    Kuroda, Hiroaki
    Shimizu, Junichi
    Horio, Yoshitsugu
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    ANTICANCER RESEARCH, 2017, 37 (11) : 6477 - 6480
12345